# Treatment of Paclitaxel Plus Carboplatin Followed by Gemcitabine Plus Carboplatin for Patients With Epithelial Ovarian Cancer

> **NCT00490711** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 7 (actual)

## Conditions studied

- Epithelial Ovarian Cancer

## Interventions

- **DRUG:** gemcitabine
- **DRUG:** carboplatin
- **DRUG:** paclitaxel

## Key facts

- **NCT ID:** NCT00490711
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-07
- **Primary completion:** —
- **Final completion:** 2005-04
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2007-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00490711

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00490711, "Treatment of Paclitaxel Plus Carboplatin Followed by Gemcitabine Plus Carboplatin for Patients With Epithelial Ovarian Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00490711. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*